- Home
- Equipment
- switzerland
- antigen specifications
Show results for
Refine by
Antigen Specifications Equipment Supplied In Switzerland
6 equipment items found
Manufactured by:Advanced Accelerator Applications SA based inRueil-Malmaison Cedex, FRANCE
LOCAMETZ, after radiolabeling with gallium-68, is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy, with suspected recurrence based on elevated serum ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including IL-13Rα2, EphA2, and survivin; 2 of these synthetic peptides (IL-13Rα2 and survivin) are mutant and believed to enhance immune activity. A multicenter Phase ...
Manufactured by:Agappe Diagnostics Switzerland GmbH based inCham, SWITZERLAND
Mispa Revo is a reliable, quick and portable immunofluorescence analyzer intended to quantitatively determine the concentrations of procalcitonin and other emergency parameters in whole-blood, plasma and ...
Manufactured by:Prima Lab SA based inBalerna, SWITZERLAND
In the long term, Helicobacter pylori infection is associated with an increased risk of gastric cancer. The search for Helicobacter pylori specific antigens in faeces is a valid and non-invasive method to rapidly identify an ...
Manufactured by:Prima Lab SA based inBalerna, SWITZERLAND
Rapid self-test for the qualitative detection of SARS-CoV-2 Nucleocapsid protein antigens in human nasal specimens. Inserted in the rapid self-test swabs list for the Emilia Romagna region, ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based ...